diabetes drug

30 Oct: Avandia one vote away from elimination

Sen. Charles Grassley, the ranking Republican on the Senate Finance Committee, says that the FDA’s Drug Safety Oversight Board voted 8-7 on Oct. 2 to keep the scandal-plagued diabetes drug Avandia on the market. The result was kept from the public. Wow, what a nailbiter. That’s enough to give Glaxo execs a heart attack (or at least increase the risk of one by, oh, 43 percent.) (Via Reuters.)

19 Oct: Exubera bong gets Pfired

Pfizer CEO Jeff Kindler has finally thrown out the Exubera baby with the bong water, saying, “We made an important decision regarding Exubera, a product for which we initially had high expectations. Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians. We have therefore concluded that further investment in this product is unwarranted.” Exubera is the first inhalable insulin diabetes drug to market but was later pulled from the market because of poor sales due to doctors concerns about its long-term safety. A video at PharmaGossip sums it up:

15 Aug: Avandia gets black-boxed

From HealthDay News: The widely used but controversial diabetes drug Avandia will now have a strong “black box” warning on its label, advising users of an increased risk of heart failure, the U.S. Food and Drug Administration announced late Tuesday. Another four diabetes drugs from the same class, including Actos, will also carry a similar black-box message, which is the agency’s strongest label warning. The FDA and the drug manufacturers, GlaxoSmithKline and Takeda Pharmaceuticals, have been negotiating the label changes since May. Studies have suggested that Avandia (rosiglitazone), made by Glaxo, and Actos (pioglitazone), made by Takeda, raise patients’ odds for heart failure. Other research has suggested that Avandia might possibly raise users’ risk for heart attack, though the FDA…